Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 4 |
2024 | 2 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x.
Blood Cancer J. 2023.
PMID: 37567878
Free PMC article.
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A, Al-Kali A, Foran JM, Elliott MA, Begna K, Badar T, Khera N, Fleti F, Abdelmagid M, Reichard KK, Ketterling RP, Pardanani A, Gangat N, Tefferi A.
Singh A, et al. Among authors: fleti f.
Am J Hematol. 2022 Oct;97(10):E377-E379. doi: 10.1002/ajh.26672. Epub 2022 Aug 12.
Am J Hematol. 2022.
PMID: 35959963
Free article.
No abstract available.
Item in Clipboard
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.
Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A.
Abdelmagid MG, et al. Among authors: fleti f.
Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.
Haematologica. 2023.
PMID: 36794509
Free PMC article.
No abstract available.
Item in Clipboard
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A.
Fleti F, et al.
Am J Hematol. 2023 Apr;98(4):E76-E79. doi: 10.1002/ajh.26845. Epub 2023 Feb 6.
Am J Hematol. 2023.
PMID: 36655582
Free article.
No abstract available.
Item in Clipboard
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R.
Tefferi A, et al. Among authors: fleti f.
Br J Haematol. 2024 Apr;204(4):1243-1248. doi: 10.1111/bjh.19247. Epub 2023 Dec 11.
Br J Haematol. 2024.
PMID: 38083865
Item in Clipboard
Integrating large language models in systematic reviews: a framework and case study using ROBINS-I for risk of bias assessment.
Hasan B, Saadi S, Rajjoub NS, Hegazi M, Al-Kordi M, Fleti F, Farah M, Riaz IB, Banerjee I, Wang Z, Murad MH.
Hasan B, et al. Among authors: fleti f.
BMJ Evid Based Med. 2024 Feb 21:bmjebm-2023-112597. doi: 10.1136/bmjebm-2023-112597. Online ahead of print.
BMJ Evid Based Med. 2024.
PMID: 38383136
Item in Clipboard
Cite
Cite